THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.17]-C164 ID: TIP-MED-000434 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Methylergometrine Maleate

Active Ingredient / Scientific Identity: Methylergometrine Maleate • Class: High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot Alkaloid & Prostaglandin F2-alpha)

⚖️ Compare Profile
Generic / Entity NameMethylergometrine Maleate ([12.17]-C164)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassHigh-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot Alkaloid & Prostaglandin
Available Dosage FormsOxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg;
Regulatory ClassificationSchedule H Prescription Drug (Single-Unit Blister Pack Mandate) • ISMP HIGH-ALERT • N
Key Warning & Review DateNo dose adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (Single-Unit Blister Pa🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Methylergometrine Maleate (TIP-MED-000434, Reference Code [12.17]-C164) is classified under Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot Alkaloid & Prostaglandin F2-alpha). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (Single-Unit Blister Pack Mandate) • ISMP HIGH-ALERT • NLEM 2022.

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [12.17] (Oxytocin, Methylergometrine Maleate & Carboprost). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.17], p. 163): Oxytocin: Pitocin (Pfizer), Syntocinon (Novartis), Evatocin (Neon — 5 IU/mL); Methylergometrine: Methergin (Novartis — 0.125 mg Tab, 0.2 mg/mL Inj), Utergin; Carboprost: Prostodin (AstraZeneca — 125 mcg/mL, 250 mcg/mL Inj) — Strengths & Forms: Oxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg; Injection: 0.2 mg/mL. Carboprost Tromethamine IM Injection: 125 mcg/mL, 250 mcg/mL.
Co-indexed constituent under primary monograph [12.17] (Oxytocin, Methylergometrine Maleate & Carboprost). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.17], p. 163): Oxytocin: Pitocin (Pfizer), Syntocinon (Novartis), Evatocin (Neon — 5 IU/mL); Methylergometrine: Methergin (Novartis — 0.125 mg Tab, 0.2 mg/mL Inj), Utergin; Carboprost: Prostodin (AstraZeneca — 125 mcg/mL, 250 mcg/mL Inj) — Strengths & Forms: Oxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg; Injection: 0.2 mg/mL. Carboprost Tromethamine IM Injection: 125 mcg/mL, 250 mcg/mL.
Dosage Forms & Available Strengths:
Oxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg; Injection: 0.2 mg/mL. Carboprost Tromethamine IM Injection: 125 mcg/mL, 250 mcg/mL.
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Binds to Gq/11-protein-coupled Oxytocin Receptors (OXTR — whose myometrial density increases 100- to 200-fold during late gestation under oestrogen priming) on uterine smooth muscle cells. Activates Phospholipase C-β, generating IP3 (releasing Ca2+ from sarcoplasmic reticulum) and DAG, which activates Ca2+-Calmodulin/MLCK to increase the frequency and force of rhythmic fundal uterine contractions while stimulating decidual prostaglandin PGF2α synthesis.

4. Therapeutic Indications & Evidence-Supported Uses

  • Active Management of the Third Stage of Labour (AMTSL) — WHO/MoHFW drug of choice to prevent and treat Postpartum Haemorrhage (PPH)
  • Induction and augmentation of labour in medically indicated term pregnancies

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Prevention of PPH (AMTSL): 10 IU Intramuscularly (IM) immediately after delivery of the anterior shoulder/infant. Treatment of PPH: 10–40 IU in 500–1000 mL Normal Saline/Ringer's Lactate infused IV. Labour Induction: Titrated via infusion pump starting at 1–2 mU/min.

Administration & Meal Timing: Intramuscular (AMTSL) or Titrated Intravenous Infusion via infusion pump (NEVER administer rapid undiluted IV bolus!).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [12.17].
Metabolism & Biotransformation:
No dose adjustment required.
Elimination & Renal Adjustment:
Monitor fluid balance during prolonged high-dose infusions (structural similarity to Vasopressin/ADH causes antidiuretic V2 water retention).
Hepatic Impairment Considerations:
No dose adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Cephalopelvic disproportion (CPD), transverse lie, placenta praevia, or vasa praevia
  • Foetal distress where delivery is not imminent, or prior classical vertical caesarean scar (risk of uterine rupture)

Key Clinical Precautions: No dose adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Uterine tachysystole / hyperstimulation (>5 contractions in 10 min), placental uteroplacental hypoperfusion, foetal bradycardia/hypoxia, and uterine rupture
  • Acute transient profound hypotension and reflex tachycardia if given as a rapid undiluted IV bolus
  • Water intoxication and dilutional hyponatraemia (seizures, coma) when high doses (>20–40 mU/min) are infused in large volumes of electrolyte-free 5% Dextrose due to ADH/V2 receptor cross-reactivity
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Misoprostol / Dinoprostone (Prostaglandins): synergistic uterine hyperstimulation and rupture — wait at least 4–6 hours after vaginal prostaglandin before starting Oxytocin
    • Vasopressors (Ephedrine, Phenylephrine): severe postpartum hypertension
    • Halogenated volatile anaesthetics (Sevoflurane, Isoflurane): relax the uterus and antagonize Oxytocin

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.17].

    Pharmacist Patient Counselling Points:

    • COLD-CHAIN MANDATE: Store Oxytocin ampoules strictly in a refrigerator at 2°C–8°C (heat exposure degrades peptide potency and leads to fatal postpartum haemorrhage).
    • Always dilute in isotonic electrolyte solutions (0.9% Normal Saline or Ringer's Lactate) rather than 5% Dextrose to prevent hyponatraemic water intoxication.
    • Never administer as a rapid IV push during caesarean section.

    Storage, Stability & Dispensing Safeguards: STRICT COLD CHAIN: Store in refrigerator at 2°C–8°C; protect from freezing and heat.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.